Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

CNS Pharmaceuticals Q3 2026 Results: Net Loss of $2.5M, Loss Narrows

CNS Pharmaceuticals reported a net loss of $10.0 million for the nine months ended September 30, 2026, while significantly strengthening its cash position to $17.2 million following a $22.5 million private placement in May 2026. The company is currently pivoting its corporate strategy toward acquiring new therapeutic assets and exploring out-licensing opportunities for its legacy glioblastoma programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-2.5-3.2
EPS (diluted, $ a share)$-0.24$-5.76

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CNSP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CNS Pharmaceuticals, Inc.: key numbers

Share price
$3.48Close, Nov 16
Market cap
$5.14M
Shares outstanding
1.48MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CNS Pharmaceuticals, Inc.

All →
8:00 AM ET 8-K
Shareholder Meeting

CNS Pharmaceuticals Shareholder Meeting

CNS Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 30, 2026, where shareholders elected six directors and ratified MaloneBailey, LLP as the independent auditor. Stockholders also approved an amendment to the 2020 Equity Plan to increase the number of authorized shares by 650,000 and approved executive compensation on an advisory basis.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.